Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors

The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Méndez-Huergo, S.P., Mascanfroni, I.D., Dergan-Dylon, S., Toscano, M.A., Caramelo, J.J., García-Vallejo, J.J., Ouyang, J., Mesri, E.A., Junttila, M.R., Bais, C., Shipp, M.A., Salatino, M., Rabinovich, G.A.
Formato:	JOUR
Materias:	Angiogenesis Inhibitors Animals Anoxia Endothelial Cells Galectin 1 Glycosylation Humans Mice Neoplasms Neovascularization, Pathologic Receptors, Mitogen Vascular Endothelial Growth Factors galectin 1 lectin receptor ligand sialic acid vasculotropin vasculotropin antibody vasculotropin receptor 2 angiogenesis animal experiment animal model animal tissue Article breast metastasis cancer inhibition controlled study depletion drug efficacy endothelium cell gene silencing glycosylation human human cell hypoxia immunocompetent cell kidney carcinoma liver cell carcinoma metastatic colorectal cancer mouse neoplasm non small cell lung cancer nonhuman protein binding protein secretion vascularization
Acceso en línea:	http://hdl.handle.net/20.500.12110/paper_00928674_v156_n4_p744_Croci
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	todo:paper_00928674_v156_n4_p744_Croci
record_format	dspace
spelling	todo:paper_00928674_v156_n4_p744_Croci2023-10-03T14:55:21Z Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors Croci, D.O. Cerliani, J.P. Dalotto-Moreno, T. Méndez-Huergo, S.P. Mascanfroni, I.D. Dergan-Dylon, S. Toscano, M.A. Caramelo, J.J. García-Vallejo, J.J. Ouyang, J. Mesri, E.A. Junttila, M.R. Bais, C. Shipp, M.A. Salatino, M. Rabinovich, G.A. Angiogenesis Inhibitors Animals Anoxia Endothelial Cells Galectin 1 Glycosylation Humans Mice Neoplasms Neovascularization, Pathologic Receptors, Mitogen Vascular Endothelial Growth Factors galectin 1 lectin receptor ligand sialic acid vasculotropin vasculotropin antibody vasculotropin receptor 2 angiogenesis animal experiment animal model animal tissue Article breast metastasis cancer inhibition controlled study depletion drug efficacy endothelium cell gene silencing glycosylation human human cell hypoxia immunocompetent cell kidney carcinoma liver cell carcinoma metastatic colorectal cancer mouse neoplasm non small cell lung cancer nonhuman protein binding protein secretion vascularization The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick © 2014 Elsevier Inc. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_00928674_v156_n4_p744_Croci
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Angiogenesis Inhibitors Animals Anoxia Endothelial Cells Galectin 1 Glycosylation Humans Mice Neoplasms Neovascularization, Pathologic Receptors, Mitogen Vascular Endothelial Growth Factors galectin 1 lectin receptor ligand sialic acid vasculotropin vasculotropin antibody vasculotropin receptor 2 angiogenesis animal experiment animal model animal tissue Article breast metastasis cancer inhibition controlled study depletion drug efficacy endothelium cell gene silencing glycosylation human human cell hypoxia immunocompetent cell kidney carcinoma liver cell carcinoma metastatic colorectal cancer mouse neoplasm non small cell lung cancer nonhuman protein binding protein secretion vascularization
spellingShingle	Angiogenesis Inhibitors Animals Anoxia Endothelial Cells Galectin 1 Glycosylation Humans Mice Neoplasms Neovascularization, Pathologic Receptors, Mitogen Vascular Endothelial Growth Factors galectin 1 lectin receptor ligand sialic acid vasculotropin vasculotropin antibody vasculotropin receptor 2 angiogenesis animal experiment animal model animal tissue Article breast metastasis cancer inhibition controlled study depletion drug efficacy endothelium cell gene silencing glycosylation human human cell hypoxia immunocompetent cell kidney carcinoma liver cell carcinoma metastatic colorectal cancer mouse neoplasm non small cell lung cancer nonhuman protein binding protein secretion vascularization Croci, D.O. Cerliani, J.P. Dalotto-Moreno, T. Méndez-Huergo, S.P. Mascanfroni, I.D. Dergan-Dylon, S. Toscano, M.A. Caramelo, J.J. García-Vallejo, J.J. Ouyang, J. Mesri, E.A. Junttila, M.R. Bais, C. Shipp, M.A. Salatino, M. Rabinovich, G.A. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
topic_facet	Angiogenesis Inhibitors Animals Anoxia Endothelial Cells Galectin 1 Glycosylation Humans Mice Neoplasms Neovascularization, Pathologic Receptors, Mitogen Vascular Endothelial Growth Factors galectin 1 lectin receptor ligand sialic acid vasculotropin vasculotropin antibody vasculotropin receptor 2 angiogenesis animal experiment animal model animal tissue Article breast metastasis cancer inhibition controlled study depletion drug efficacy endothelium cell gene silencing glycosylation human human cell hypoxia immunocompetent cell kidney carcinoma liver cell carcinoma metastatic colorectal cancer mouse neoplasm non small cell lung cancer nonhuman protein binding protein secretion vascularization
description	The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually reinitiate growth. Here, we identify a glycosylation-dependent pathway that compensates for the absence of cognate ligand and preserves angiogenesis in response to VEGF blockade. Remodeling of the endothelial cell (EC) surface glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-glycans on VEGFR2, activated VEGF-like signaling. Vessels within anti-VEGF-sensitive tumors exhibited high levels of α2-6-linked sialic acid, which prevented Gal1 binding. In contrast, anti-VEGF refractory tumors secreted increased Gal1 and their associated vasculature displayed glycosylation patterns that facilitated Gal1-EC interactions. Interruption of β1-6GlcNAc branching in ECs or silencing of tumor-derived Gal1 converted refractory into anti-VEGF-sensitive tumors, whereas elimination of α2-6-linked sialic acid conferred resistance to anti-VEGF. Disruption of the Gal1-N-glycan axis promoted vascular remodeling, immune cell influx and tumor growth inhibition. Thus, targeting glycosylation-dependent lectin-receptor interactions may increase the efficacy of anti-VEGF treatment. PaperFlick © 2014 Elsevier Inc.
format	JOUR
author	Croci, D.O. Cerliani, J.P. Dalotto-Moreno, T. Méndez-Huergo, S.P. Mascanfroni, I.D. Dergan-Dylon, S. Toscano, M.A. Caramelo, J.J. García-Vallejo, J.J. Ouyang, J. Mesri, E.A. Junttila, M.R. Bais, C. Shipp, M.A. Salatino, M. Rabinovich, G.A.
author_facet	Croci, D.O. Cerliani, J.P. Dalotto-Moreno, T. Méndez-Huergo, S.P. Mascanfroni, I.D. Dergan-Dylon, S. Toscano, M.A. Caramelo, J.J. García-Vallejo, J.J. Ouyang, J. Mesri, E.A. Junttila, M.R. Bais, C. Shipp, M.A. Salatino, M. Rabinovich, G.A.
author_sort	Croci, D.O.
title	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
title_short	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
title_full	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
title_fullStr	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
title_full_unstemmed	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
title_sort	glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-vegf refractory tumors
url	http://hdl.handle.net/20.500.12110/paper_00928674_v156_n4_p744_Croci
work_keys_str_mv	AT crocido glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT cerlianijp glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT dalottomorenot glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT mendezhuergosp glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT mascanfroniid glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT dergandylons glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT toscanoma glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT caramelojj glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT garciavallejojj glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT ouyangj glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT mesriea glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT junttilamr glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT baisc glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT shippma glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT salatinom glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors AT rabinovichga glycosylationdependentlectinreceptorinteractionspreserveangiogenesisinantivegfrefractorytumors
_version_	1782023825515347968

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors

Ejemplares similares